Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
83.94
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
34
35
Next >
10 Biggest Price Target Changes For Monday
March 22, 2022
Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading.
Via
Benzinga
What Cramer Thinks About Hims & Hers Health, Gilead Sciences And More
March 21, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Healthcare Realty Trust Incorporated (NYSE: HR) as the company’s merger with Healthcare Trust of America, Inc.
Via
Benzinga
Buy These 3 High-Yield Stocks If You're In Your 50s And Cruise Into Retirement
March 21, 2022
In your 50s and looking for age-appropriate investments? Fancy yourself some hefty income in lieu of big growth as you age? Want to glide into retirement and land on a sheet of big, safe, totally...
Via
Talk Markets
High Dividend 50: Gilead Sciences
March 18, 2022
Gilead is offering an all-time high dividend yield of 5.0% and is trading at a forward price-to-earnings ratio of 9.1. Unfortunately, there are good reasons behind these seemingly attractive features...
Via
Talk Markets
Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
March 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Moderna Rockets As It Attempts The Impossible: Vaccinating Against HIV
March 14, 2022
It hasn't been possible to vaccinate against HIV. Does Moderna stand a chance?
Via
Investor's Business Daily
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
March 11, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.58% on an annualized basis. Buying $100 In GILD: 20 years ago, an investor could have...
Via
Benzinga
Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint
March 07, 2022
Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic...
Via
Benzinga
How A Mixed Breast Cancer Study Cast Doubt On Gilead's Immunomedics Buyout
March 07, 2022
Gilead's Trodelvy had mixed test results in patients with breast cancer.
Via
Investor's Business Daily
36 Stocks To Watch After Biden's First State of The Union Address
March 02, 2022
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped...
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection
March 01, 2022
The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ: GILD) application for lenacapavir for heavily treated multi-drug...
Via
Benzinga
Where Gilead Sciences Stands With Analysts
February 28, 2022
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Tumble Following New Sanctions Against Russia
February 28, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones surged more than 800 points in the previous session. Investors are awaiting earnings...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
February 25, 2022
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.
Via
InvestorPlace
Is Moderna the Next Gilead or the Next Regeneron?
February 22, 2022
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed.
Via
InvestorPlace
"Prudent" Biotech Bets
February 20, 2022
Here, we review two recommended biotechnology stocks following the release of their latest earnings reports. Let's take a look.
Via
Talk Markets
See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization
February 18, 2022
The FDA has revised the Emergency Use Authorization (EUA) for Merck & Co Inc's (NYSE: MRK) COVID-19 pill molnupiravir, explaining that it should be...
Via
Benzinga
Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients
February 17, 2022
Gilead Sciences Inc (NASDAQ: GILD) announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir in heavily pretreated multi-drug...
Via
Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...
Via
Benzinga
Hookipa Pharma Stock Surges On HIV Pact With Gilead
February 16, 2022
Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
February 16, 2022
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector.
Via
Talk Markets
Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients
February 14, 2022
Gilead Sciences Inc (NASDAQ: GILD) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.